New: NCI-funded clinical trial search
Mednet Logo
CommunityRheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How often do you draw screening ANAs for discoid lupus?

1
4 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Because a positive ANA is associated with an increased risk of progression to SLE in patients with discoid lupus, I routinely check an ANA at the initial visit in virtually all patients. If negative, I repeat it only if new symptoms concerning systemic involvement arise (e.g., joint pain, cytopenias...

Would you expect to see severe arthralgias within the first few days of immune-therapy in a patient without history of autoimmune disease?

1
2 Answers

Mednet MemberInvited Expert
Rheumatology · Ohio State University

The short answer is: Absolutely!The long answer is:From a mechanistic standpoint, it is common to see severe arthralgias within days of initiating immune checkpoint inhibition, even in a patient without a prior autoimmune diagnosis.Checkpoint inhibitors rapidly release inhibitory signals on T-cell a...

How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?

1
1 Answers

Mednet MemberInvited Expert
Rheumatology · Director, Vasculitis Clinical Research Consortium

The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:The data from ADVOCATE indicate that patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) treated with avacopan 30 mg twice daily and prednisone placebo were able to achieve remission w...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?

5
10 Answers

Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

I'll approach this from the cost-effectiveness standpoint as I agree with Drs. @Dr. First Last and @Dr. First Last on their excellent points.Patients with SLE have remarkably high costs when you add up copays, medications, imaging studies, travel, missing work, etc. Anything we can do to help reduce...

As a primary care provider, how do I reconcile the different types of immunosuppression? I realize that solid organ transplant immunosuppression is much more intense and riskier compared to medications like Humira or Dupixent, or an undetectable viral load in HIV. How do these differences affect cervical cancer screening?

1
1 Answers

Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

Dr. @Dr. First Last, I like this question a lot. We rheumatologists can tend to forget how complicated this topic can be.I. Hydroxychloroquine (Plaquenil), the #1 drug to treat SLE, is often mistaken as an immunosuppressant, but it is not. It is an immunomodulatory therapy without true immunosuppres...

How do you assess the risk of developing demyelinating disease when initiating TNF inhibitors?

2 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

First, a bit of history. In the 1990s, TNFi were studied as potential drugs to treat multiple sclerosis (MS). One product in particular, lenercept a soluble p55 TNF receptor IgG fusion protein, showed promise in animal models of MS. However, in phase II trials studying its role as a treatment for MS...

Are there particular subsets of AAV patients in which avacopan is more effective?

1 Answers

Mednet MemberInvited Expert
Rheumatology · Director, Vasculitis Clinical Research Consortium

The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:Patients in the ADVOCATE trial were stratified at entry according to time of diagnosis (new/relapsing), diagnosis (GPA/MPA), ANCA serotype (PR3/MPO), and background immunosuppressive (cyclophosphamide/rituximab) with re...

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center

First of all, I wish to thank @Dr. First Last from Johns Hopkins/Sibley for his advice addressing this critical topic.We are all witnessing a rapidly evolving crisis that none of us have been prepared for and it is the right thing to quickly consider as best as we can how the COVID-19 pandemic shoul...

How do you approach the management of a patient with strongly positive SSA antibodies and an extraglandular feature such as ILD or peripheral neuropathy, but without sicca symptoms or parotid abnormalities?

1
3 Answers

Mednet Member
Rheumatology · Duke University

The ACR/EULAR 2016 criteria are clear that a patient with a +SSA antibody needs to also have some degree of measurable sicca in order to be clinically diagnosed with SjD. In my experience, many patients may not perceive that they are dry because they have been able to tolerate the symptoms over time...